Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 480 participants.

Also called NCT05028140

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 480 participants (planned count) (from the registry)
Sponsor
EMS (from the registry)
Registry
  • NCT NCT05028140
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Brazil (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05028140. Randomized; double masking; primary purpose treatment. Start 2024-10-08 (actual); primary completion 2026-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus
Acronym
PIEMONTE
Condition
Type II Diabetes
Intervention (Drug)
PIEMONTE
Intervention (Other)
PIEMONTE PLACEBO
Intervention (Drug)
EMPAGLIFLOZIN
Intervention (Other)
PLACEBO EMPAGLIFLOZIN
Intervention (Drug)
PIOGLITAZONE
Intervention (Other)
PLACEBO PIOGLITAZONE
Lead sponsor
EMS (class: industry)

Record details

Record id
cardio:ct-nct05028140
Content hash
3614d4dd347de734abdaf8662d5a90e9f76d9a8cef2810a1271727ecd1e61b6c